An international clinical trial published in the Lancet with patients recruited from Manchester and Sheffield has shown that dupilumab is
highly effective in controlling severe eczema in children has young as 6 months old.
Although the medicine is currently only available in the UK for children 6 years and older, it it hoped that it will be available in 2023 for younger children.
To read full article click here.